Pierre Fabre offers an extensive portfolio of prescription drugs covering major treatment fields such as neuropsychiatry, gynecology, urology, cardiology, diabetes and respiratory diseases. These products come mainly from co-marketing partnerships with other laboratories.
The company has long been interested in feminine health. Pierre Fabre particularly contributed to the recognition of chronic vein insufficiency by the medical profession in the 1960s. Towards the end of the 1980s, feminine health became an even more important focus of the group, when it took over the Swiss Robapharm laboratories. With this takeover, Tardyferon® and Ossopan® were incorporated in the range of treatment solutions for women. Since then, the range has continued to develop. Today we are represented in over 70 countries and in 8 treatment fields focusing on feminine health.
With a desire to comprehensively meet the demand for the care of female patients, we have extended our product portfolio over time and today we cover 8 major therapeutic areas for feminine health:
- Iron and calcium deficiency
- Urinary incontinence
- Gynecological infections
- Urinary infections
- Overweight and aesthetic issues
- Hormone replacement therapy during menopause
Our network of medical sales representatives visits 35,000 gynecologists in more than 50 countries. We have a close relationship with healthcare professionals who understand more than anyone the needs of their female patients and are able to advise them. We have therefore become the leading pharmaceutical company in France in terms of medical visits to gynecologists, as well as in other countries.
Pierre Fabre’s involvement in neuropsychiatry dates from the late 1980s, with the development of a molecule from Pierre Fabre research registered to treat depression in Europe and fibromyalgia in the United States.
Our presence in the field of major depressive disorders extends over 45 countries, including many European countries (Austria, Finland, France, Portugal, Russia, etc.), as well as Japan, the Middle East, in several Latin American countries (Argentina, Chile, Mexico).
In 2008, we signed a license agreement with the American pharmaceutical company Forest Laboratories, Inc. to develop an antidepressant using a molecule discovered by the Pierre Fabre research teams. In the wake of the Phase III studies, finalized in 2012, Forest began marketing it in the United States in January 2014 under the name of Fetzima (levomilnacipran).
Our commitment to neuropsychiatry research aims to provide new therapeutic solutions in the medium-to-long term for the treatment of schizophrenia, bipolar disorders, neurodegenerative disorders, depressive disorders, and chronic pain.
Permixon® is indicated in urology. Its main active ingredient comes from the berries of Serenoa Repens, a palm tree native of Florida. The berries are harvested by suppliers who are audited according to the quality and traceability requirements prescribed in the set of specifications for our Botanical Expertise Pierre Fabre certified program. The berries are harvested according to the Agricultural and Harvesting Best Practices without adversely affecting the sustainability of this resource. The production of Serenoa Repens for the manufacture of Permixon® amounts to approximately 400 metric tons per year. They are transferred to Gaillac (Tarn, France) where the active ingredient is manufactured using a special extraction process (hexane extraction) that gives Permixon® its unique, notably pharmacological properties. Permixon®,one of Pierre Fabre’s leading drugs, is an integral part of the Botanical Expertise Pierre Fabre program, which has been certified by the European Foundation for Quality Management (EFQM) since 2010.
treatment of benign prostatic hypertrophy
Treatment of hypertension
Secondary prevention of MI
Treatment of Type 2 diabetes
Representatives of DDP4, the latest class of oral hypoglycemic drug